Payment overview · 2025
General Payments
$1,077.43
72 reported records · 13 companies
Healthcare provider profile · identity verified
Phillip A. Haddad, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SHAWNEE, OK · NPI 1326087818
Verified facts
What the public records show
CMS Open Payments records show Phillip A. Haddad, M.D. received $1,077.43 in general payments during 2025 across 72 reported records.
GlaxoSmithKline, LLC. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fasenra, Tezspire, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FASENRA as an associated drug or biological on 40035 records involving 10417 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fasenra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Tezspire by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ofev by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 1294 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $224.45 | 20.8% | 21 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $184.73 | 17.1% | 11 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $174.48 | 16.2% | 11 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $154.99 | 14.4% | 11 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $109.55 | 10.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.40 | 7.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.12 | 3.7% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $27.91 | 2.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.17 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.72 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.93 | 1.4% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $14.73 | 1.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.25 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,077.43 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $264.54 | 16 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $185.71 | 17 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $184.73 | 11 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $174.48 | 11 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $78.40 | 4 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $40.12 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.74 | 4 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $27.91 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FASENRA fasenra |
2025 | Fasenra | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 1294 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FASENRA open payments reported associated product |
CMS Open Payments — General Payments 40035 supporting records · 10417 recipient NPIs · example record 1206131346 |
Fasenra · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
158 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
87 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
1294 | 246 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 1824 | 495 |
| Prednisone | Prednisone | 1342 | 526 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 1294 | 246 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1027 | 329 |
| Azithromycin | Azithromycin | 859 | 283 |
| Omeprazole | Omeprazole | 560 | 175 |
| Losartan Potassium | Losartan Potassium | 469 | 145 |
| Fluticasone Propionate | Fluticasone Propionate | 378 | 156 |
| Gabapentin | Gabapentin | 376 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 85 |
| Cefuroxime | Cefuroxime Axetil | 311 | 194 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 241 | 69 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 222 | 62 |
| Levofloxacin | Levofloxacin | 212 | 105 |
| Ventolin Hfa | Albuterol Sulfate | 189 | 63 |
| Furosemide | Furosemide | 187 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 182 | 54 |
| Breo Ellipta | Fluticasone/Vilanterol | 182 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 180 | 54 |
| Eliquis | Apixaban | 166 | 40 |
| Potassium Chloride | Potassium Chloride | 162 | 58 |
| Symbicort | Budesonide/Formoterol Fumarate | 158 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 30 |
| Alprazolam | Alprazolam | 136 | 29 |
| Famotidine | Famotidine | 127 | 60 |
| Glimepiride | Glimepiride | 125 | 36 |
| Carvedilol | Carvedilol | 117 | 35 |
| Simvastatin | Simvastatin | 115 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 102 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 30 |
| Tramadol Hcl | Tramadol Hcl | 100 | 24 |
| Pregabalin | Pregabalin | 94 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 94 | 30 |
| Diazepam | Diazepam | 91 | 18 |
| Metformin Hcl | Metformin Hcl | 91 | 25 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 90 | 18 |
| Ofev | Nintedanib Esylate | 87 | 11 |
| Torsemide | Torsemide | 83 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 25 |
| Azelastine Hcl | Azelastine Hcl | 81 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 40 |
| Trulicity | Dulaglutide | 81 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 77 | 29 |
| Lisinopril | Lisinopril | 76 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 75 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 22 |
| Fluconazole | Fluconazole | 68 | 27 |
| Meloxicam | Meloxicam | 67 | 23 |
| Methylprednisolone | Methylprednisolone | 63 | 35 |
| Xarelto | Rivaroxaban | 63 | 13 |
| Ozempic | Semaglutide | 62 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 60 | 14 |
| Mounjaro | Tirzepatide | 60 | 12 |
| Sertraline Hcl | Sertraline Hcl | 59 | 21 |
| Spiriva Handihaler | Tiotropium Bromide | 57 | suppressed |
| Nystatin | Nystatin | 53 | 17 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 48 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 45 | 15 |
| Ibuprofen | Ibuprofen | 44 | 16 |
| Ondansetron Odt | Ondansetron | 44 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 26 |
| Lansoprazole | Lansoprazole | 42 | 12 |
| Theophylline Er | Theophylline Anhydrous | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 24 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 11 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 35 | 11 |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 32 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | 12 |
| Colestipol Hcl | Colestipol Hcl | 31 | 13 |
| Roflumilast | Roflumilast | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Zafirlukast | Zafirlukast | 27 | suppressed |
| Fasenra Pen | Benralizumab | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 11 |
| Primidone | Primidone | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Tezspire | Tezepelumab-Ekko | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Azathioprine | Azathioprine | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Fasenra | Benralizumab | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ulticare Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,077.43 · 72 records | GlaxoSmithKline, LLC. | CAMZYOS, DUPIXENT, FASENRA, Hillrom - Monarch Airway Clearance System, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JASCAYD, NUCALA, NURTEC ODT, Ohtuvayre, TEZSPIRE, TRELEGY ELLIPTA, Vest Therapy Und, YUPELRI, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fasenra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error